Lizhu Lin
- Oncology top 10%
- Pulmonary and Respiratory Medicine top 10%
- Molecular Biology
- Cancer Research
- Otorhinolaryngology top 5%
- Co-authors
- Yuanyuan ZhaoYunpeng YangYan HuangXue HouLikun ChenYang ZhangJianping XiongXiaohui He
- Topics
- Traditional Chinese Medicine Studies (7 papers)Cancer Immunotherapy and Biomarkers (5 papers)Cancer-related molecular mechanisms research (4 papers)
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Lizhu Lin
44 papers receiving 758 citations
Hit Papers
Peers
Comparison fields: 5 of 86
- Oncology 397
- Pulmonary and Respiratory Medicine 239
- Molecular Biology 228
- Cancer Research 131
- Otorhinolaryngology 121
Countries citing papers authored by Lizhu Lin
This map shows the geographic impact of Lizhu Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lizhu Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lizhu Lin more than expected).
Fields of papers citing papers by Lizhu Lin
This network shows the impact of papers produced by Lizhu Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lizhu Lin. The network helps show where Lizhu Lin may publish in the future.
Co-authorship network of co-authors of Lizhu Lin
This figure shows the co-authorship network connecting the top 25 collaborators of Lizhu Lin. A scholar is included among the top collaborators of Lizhu Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lizhu Lin. Lizhu Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 7 | |
| 3 | 13 | |
| 4 | 1 | |
| 5 | 4 | |
| 6 | 4 | |
| 7 | 8 | |
| 8 | 5 | |
| 9 | 5 | |
| 10 | 3 | |
| 11 | 11 | |
| 12 | 0 | |
| 13 | 4 | |
| 14 | 3 | |
| 15 | 13 | |
| 16 | 24 | |
| 17 | 1 | |
| 18 | Clinical Experiences of Professor LIN Lizhu in Treating Lung Cancer Using Chinese Combined Western Medicine Therapy | 1 |
| 19 | 30 | |
| 20 | Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trialsbreakdown → | 326 |
About Lizhu Lin
Lizhu Lin is a scholar working on Complementary and alternative medicine, Otorhinolaryngology and Cancer Research, having authored 47 papers that have together received 766 indexed citations. Recurring topics across this work include Traditional Chinese Medicine Studies (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer-related molecular mechanisms research (4 papers). The work is most often cited by research in Otorhinolaryngology (121 citations), Oncology (397 citations) and Cancer Research (131 citations). Lizhu Lin has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Yuanyuan Zhao, Yunpeng Yang, Yan Huang, Xue Hou, Likun Chen, Yang Zhang, Jianping Xiong, Xiaohui He, Li Zhang and Wenfeng Fang. Their work appears in journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.